Skip to main content

Dementia Research: What’s on the Horizon

Research Forum 2025

Event Date:

Event Details

Date: September 18, 2025
Time: 7 – 8:30 pm
Location: Centre Culturel Franco-Manitobain, 340 Provencher Blvd, Winnipeg, MB (and live-streamed in 4 regional locations)
Dementia research

About this event:

Dr. Donald Weaver is BACK by popular demand!


Do you have questions about the causes of dementia? Are you interested to know the risk factors of dementia? Are there new treatment options that are being researched? This is your chance to ask an expert live, in person and for free!

WinnipegCentre Culturel Franco-Manitobain (CCFM), 340 Provencher Blvd.

Unable to make it to our in person event in Winnipeg? Join us in person at one of our live streaming locations across the province to watch Dr. Weaver and connect with other community members and families who might be experiencing dementia.

Live streaming viewing parties (attend in person at any of the following locations):

Brandon (Map): Alzheimer Society of Manitoba – Westman Region Office, Unit 4B – 457 9th St.

Portage la Prairie (Map): Herman Prior Activity Centre, 40 Royal Rd. N.

Selkirk (Map): Gordon Howard Seniors’ Centre, 384 Eveline St.

Winkler (Map): Buhler Active Living Centre, #105 – 650 South Railway Ave.

Some potential topics will be:

  • Risk factors
  • Risk reduction
  • Diagnosis
  • Treatment
  • Progression
  • Quality of life

About Dr. Donald Weaver, MD, PhD, FRCPC, FCAHS:

Dr. Donald Weaver is a Senior Scientist at the Krembil Brain Institute (University Health Network, Toronto) and Professor of Medicine (Neurology) and Chemistry at the University of Toronto, where he also holds the Krembil Chair in Drug Discovery for Alzheimer’s Disease.  He obtained his MD and PhD from Queen’s University and has been a Professor of Neurology and Chemistry at Queen’s University (1989-2001), Dalhousie University (2001-2013) and the University of Toronto (2013 – present). He cofounded multiple biotech companies and is currently Chief Medical Officer of Treventis Corp. He published more than 350 papers on drug design for neurological diseases and holds 47 patents on drug discoveries. Two of Dr. Weaver’s compounds reached Phase III human clinical trials.  His current research is focused on the role of neuroinflammation in Alzheimer’s disease. 

How to register:

Fore more details, please contact Jennifer Vicente-Licardo at alzeducation@alzheimer.mb.ca or 204-943-6622.